Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s EBITDA?
- Monte Rosa Therapeutics, Inc. (GLUE) reported EBITDA of -$47.22M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s EBITDA changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s EBITDA decreased by 251.6% year-over-year, from -$13.43M to -$47.22M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s EBITDA?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s EBITDA has grown at a -13.5% compound annual growth rate (CAGR), from -$70.8M to -$45.85M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Monte Rosa Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude